Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...4142434445464748495051...5960»
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. (Pubmed Central) -  May 19, 2020   
    The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.
  • ||||||||||  Journal:  The acromegalic spine: fractures, deformities and spinopelvic balance. (Pubmed Central) -  May 19, 2020   
    The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment. Increased number of vertebral fractures and high prevalence of spinal deformities related to sagittal imbalance were detected, indicating the importance of monitoring bone comorbidities in acromegaly, with radiological evaluation of the spine as part of the follow up.
  • ||||||||||  Journal:  Double pituitary adenomas in a large surgical series. (Pubmed Central) -  May 19, 2020   
    Double pituitary adenoma is a rare entity that can pose a significant challenge especially in the setting of Cushing's disease. Careful inspection of preoperative MRI and diagnostic work-up before transsphenoidal surgery and thorough histopathological microscopic examinations with immunohistochemical staining for all pituitary hormones is essential for establishing the diagnosis of double pituitary adenoma.
  • ||||||||||  Retrospective data, Journal:  T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. (Pubmed Central) -  May 18, 2020   
    Careful inspection of preoperative MRI and diagnostic work-up before transsphenoidal surgery and thorough histopathological microscopic examinations with immunohistochemical staining for all pituitary hormones is essential for establishing the diagnosis of double pituitary adenoma. Our study confirms that hypo/isointense prolactinoma is a rare finding and suggests for the first time that the heterogeneity of prolactinoma T2 signal at diagnosis might be correlated with a different clinical behavior and could be used as a negative predictor factor of hormonal response to DA.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Clinical, Journal:  New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria. (Pubmed Central) -  May 16, 2020   
    The current study demonstrates a significant clinical and socio-economic burden of acromegaly in the country. Proper diagnosing and regular follow up of acromegaly patients in a specialized pituitary center ensure appropriate innovative pharmacotherapy with achievement of disease control.
  • ||||||||||  [VIRTUAL] Ancillary Symposium: Improving Outcomes in Acromegaly: Let Patients Be Your Guide () -  May 15, 2020 - Abstract #ENDOI2020ENDO-I_6;    
    for supporting this program Through didactic presentations and challenging case scenarios, this program will provide an opportunity to address the pathophysiology and clinical symptomology, examine common comorbidities, review treatment options associated with acromegaly and encourage health care professionals to change their practice behaviors to improve their patients’ health. Learning Objectives Upon completion of this educational activity, learners will be able to: Assess the pathophysiology and clinical symptomology associated with acromegaly to improve patient recognition and diagnosis Examine common comorbidities associated with acromegaly and the burden on patient quality of life despite endocrine control Review the latest clinical evidence regarding emerging treatments for the management of patients with acromegaly Evaluate the importance of communicating with patients regarding their disease state and realistic treatment expectations.
  • ||||||||||  Signifor LAR (pasireotide) / Novartis
    P3 data, Clinical Trial,Phase III, Journal:  Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III (PAOLA) study. (Pubmed Central) -  May 9, 2020   
    P3
    Learning Objectives Upon completion of this educational activity, learners will be able to: Assess the pathophysiology and clinical symptomology associated with acromegaly to improve patient recognition and diagnosis Examine common comorbidities associated with acromegaly and the burden on patient quality of life despite endocrine control Review the latest clinical evidence regarding emerging treatments for the management of patients with acromegaly Evaluate the importance of communicating with patients regarding their disease state and realistic treatment expectations. In this patient population with a high burden of comorbid illness, pasireotide was well tolerated and efficacious, providing prolonged maintenance of biochemical control and improving symptoms.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
    Journal:  How to Position Pasireotide LAR Treatment in Acromegaly. (Pubmed Central) -  May 7, 2020   
    With respect to pasireotide-induced hyperglycemia, we recommend a more liberal strategy of blood glucose monitoring during pasireotide treatment. In contrast to the current consensus criteria, we recommend a more reluctant use of pasireotide LAR therapy for the treatment of acromegaly.
  • ||||||||||  Clinical, Journal:  Acromegaly can be cured by first-line pasireotide treatment? (Pubmed Central) -  Apr 22, 2020   
    Using highly sensitive GH assay, a GH nadir ≥ 0.4 µg/L during the OGTT-GH suppression test may be used for diagnosis of acromegaly in patients with AGM in the absence of poorly controlled diabetes. No abstract available
  • ||||||||||  Clinical, Review, Journal, HEOR:  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. (Pubmed Central) -  Apr 22, 2020   
    Particularly, we analyse and describe the relationship between biochemical, as well as clinical disease control in patients with acromegaly receiving medical therapy, with a focus on comorbidities and QoL. In conclusion, we found that current literature data seem to indicate that clinical disease control (besides biochemical control), encompassing clinical signs and symptoms, comorbidities and QoL, emerge as a primary focus of acromegaly patient management.
  • ||||||||||  Review, Journal:  Hypertension and Acromegaly. (Pubmed Central) -  Apr 22, 2020   
    Although the pathogenesis has not been fully elucidated, it probably results from concomitant factors leading to expansion of extracellular fluid volume, increase of peripheral vascular resistance, and development of sleep apnea syndrome. Because the effect of normalization of growth hormone and insulinlike growth factor 1 excess on blood pressure levels is unclear, an early diagnosis of hypertension and prompt antihypertensive treatment are eagerly recommended, regardless of the specific treatment of the acromegalic disease and the level of biochemical control attained.
  • ||||||||||  Journal:  Pericardial Effusion as an Initial Presentation of Panhypopituitarism. (Pubmed Central) -  Apr 21, 2020   
    Pericardial effusion is an extremely rare manifestation of secondary hypothyroidism. To recognize the clinical presentation of cardiac tamponade.To recognize atypical causes of pericardial effusion, such as severe panhypopituitarism.Hormonal replacement is efficient in treating panhypopituitarism.
  • ||||||||||  Journal:  Improvement of acromegaly control with multimodal therapy in Romania. (Pubmed Central) -  Apr 16, 2020   
    In the second group (historical controls) there were 42 patients surgery being the most used treatment. Surgical cure rate was, 9.7% and disease control with medical treatment was 15.4% Random GH and IGF-1 after surgery were lower in the first group (p<0.05) CONCLUSIONSː Changes in Romanian protocol and highly specialized pituitary centers improve cure rate and disease control in patients with acromegaly.
  • ||||||||||  Journal:  Letter to the Editor. Upfront GKS for Cushing's disease and acromegaly: is it suitable? (Pubmed Central) -  Apr 16, 2020   
    Surgical cure rate was, 9.7% and disease control with medical treatment was 15.4% Random GH and IGF-1 after surgery were lower in the first group (p<0.05) CONCLUSIONSː Changes in Romanian protocol and highly specialized pituitary centers improve cure rate and disease control in patients with acromegaly. No abstract available
  • ||||||||||  Review, Journal:  Primary tumors of the posterior pituitary: A systematic review. (Pubmed Central) -  Apr 14, 2020   
    Different types of PPT share similar epidemiology, clinical manifestations and surgical outcomes. Surgery is the only curative option but complications and subtotal resection are common.
  • ||||||||||  Clinical, Journal:  Familial Cancer Clustering in Patients with Prolactinoma. (Pubmed Central) -  Apr 10, 2020   
    In particular, there is a strong association between prolactinoma and family history of breast and lung cancers. Further research of possible shared genetic susceptibility of prolactinoma and breast and lung cancers is needed.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    Review, Journal:  Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement. (Pubmed Central) -  Apr 10, 2020   
    This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
  • ||||||||||  Journal:  Acromegaly in digital art. (Pubmed Central) -  Apr 10, 2020   
    The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach. No abstract available
  • ||||||||||  Clinical, Journal:  Pituicytoma associated with Acromegaly and Cushing´s disease. Report of two cases. (Pubmed Central) -  Apr 10, 2020   
    The coexistence of these 2 entities may not just be a mere coincidence but may be due to a yet unknown pathophysiologic link or common progenitor lineage of both lesions. Association between pituicytoma and pituitary adenoma is increasingly being reported.
  • ||||||||||  Journal:  The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc. (Pubmed Central) -  Apr 9, 2020   
    Combined with c-Myc inhibitor 10058-F4, PRDM2 further inhibited cell proliferation and induced more apoptosis in GH3 cell. Taken together, we found that PRDM2 negatively regulated the expression of c-Myc in somatotroph adenomas, and testified the synergism between PRDM2 gene therapy and c-Myc inhibitor in vitro experiment.
  • ||||||||||  Enrollment closed:  The Treatment and Natural History of Acromegaly (clinicaltrials.gov) -  Apr 8, 2020   
    P=N/A,  N=117, Active, not recruiting, 
    Taken together, we found that PRDM2 negatively regulated the expression of c-Myc in somatotroph adenomas, and testified the synergism between PRDM2 gene therapy and c-Myc inhibitor in vitro experiment. Completed --> Active, not recruiting